METHOD FOR DETECTING CD19 EXPRESSION
    7.
    发明公开

    公开(公告)号:US20240352531A1

    公开(公告)日:2024-10-24

    申请号:US18432678

    申请日:2024-02-05

    IPC分类号: C12Q1/6886

    摘要: The present invention belongs to the technical field of molecular biology, and specifically relates to the technical field of efficacy monitoring of a chimeric antigen receptor (CAR)-T cell therapy. The present invention provides use of a primer combination in the preparation of a product for detecting a prognostic effect of an anti-CD19 CAR-T cell therapy in a tumor, where the primer combination includes primers shown in Table 1. The present invention provides use of a primer combination in the preparation of a product for detecting an expression state of CD19 on a surface of a tumor cell in a tumor patient, where the primer combination includes primers shown in Table 1. The present invention provides a product for detecting a prognostic effect of an anti-CD19 CAR-T cell therapy in a tumor, where the product includes primers shown in Table 1 as effective components.

    METHODS FOR ISOLATING CELL-FREE DNA
    8.
    发明公开

    公开(公告)号:US20240352449A1

    公开(公告)日:2024-10-24

    申请号:US18589331

    申请日:2024-02-27

    IPC分类号: C12N15/10 C12Q1/6886

    摘要: Disclosed herein are methods for isolating DNA, such as cell-free DNA (cfDNA) or DNA from a tissue sample, e.g., in which the DNA is partitioned into hypermethylated and hypomethylated partitions. After differential tagging of the partitions, portions of the hypomethylated partition are pooled with the hypermethylated partition or pooled separately. Epigenetic and sequence-variable target regions are captured from the pool comprising DNA from the hypermethylated and hypomethylated partitions, and sequence-variable target regions are captured from the pool comprising DNA from the hypomethylated partition. This approach can reduce costs and/or bandwidth by limiting sequencing of epigenetic target regions from the hypomethylated partition, which may be less informative than other DNA.

    Methods for detecting an aneurysm

    公开(公告)号:US12123057B2

    公开(公告)日:2024-10-22

    申请号:US16950825

    申请日:2020-11-17

    IPC分类号: C12Q1/6883 C12Q1/6886

    摘要: The present application provides an in vitro method for determining the degradation of the extracellular matrix (ECM) in a subject, the method comprising determining in an isolated sample from the subject the level of an expression product of at least one gene selected from the group consisting of collagen type V alpha 1 chain (COL5A1), transforming growth factor beta-1 (TGFB1), integrin subunit alpha 4 (ITGA4), integrin subunit beta 1 (ITGB1), matrix metallopeptidase 2 (MMP2), matrix metallopeptidase 9 (MMP9) and bone morphogenetic protein 1 (BMP1), the at least one gene being determined optionally in combination with one or both of collagen type XI alpha 1 chain (COL11A1) and collagen type V alpha 2 chain (COL5A2), wherein when the level of the expression product(s) is(are) higher than a reference value this is indicative of a degraded ECM. Methods for the diagnosis and prognosis of cancer and aneurysms are also provided. Furthermore, means for determining the level of expression product of the genes in the above diagnosis or prognosis methods are also provided, as well as kits containing said means.